{"id":59870,"date":"2024-08-20T01:04:25","date_gmt":"2024-08-19T23:04:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bostongene-showcases-ai-powered-multiomics-platform-at-the-22nd-annual-meeting-of-japanese-society-of-digital-pathology-in-2024\/"},"modified":"2024-08-20T01:04:25","modified_gmt":"2024-08-19T23:04:25","slug":"bostongene-showcases-ai-powered-multiomics-platform-at-the-22nd-annual-meeting-of-japanese-society-of-digital-pathology-in-2024","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bostongene-showcases-ai-powered-multiomics-platform-at-the-22nd-annual-meeting-of-japanese-society-of-digital-pathology-in-2024\/","title":{"rendered":"BostonGene Showcases AI-Powered Multiomics Platform at the 22nd Annual Meeting of Japanese Society of Digital Pathology in 2024"},"content":{"rendered":"
\n

\nBostonGene\u2019s Chief Scientific Officer, Joe Lennerz, MD, PhD, to lead a session on the evolving landscape of digital pathology and present two abstracts on AI-based imaging analysis technologies to improve patient care<\/i><\/p>\n

WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene<\/a>, a leading provider of AI-driven molecular and immune profiling solutions, today announced that two abstracts have been accepted for the 22nd Annual Meeting of the Japanese Society of Digital Pathology in 2024, scheduled to take place August 29 – 31, 2024, at Meio University in Nago, Japan.<\/p>\n

<\/a>
<\/a><\/p>\n

\nAt the meeting, Jochen \u201cJoe\u201d Lennerz, MD, PhD, Chief Scientific Officer at BostonGene will deliver a talk titled \u201cRegulatory Horizons: Shaping the Future of Digital Pathology and AI<\/i><\/b>\u201d on <\/b>Thursday,<\/b> August 29 at 3:00 PM.<\/p>\n

\nThe talk will delve into the integration of AI, molecular diagnostics and advanced data services, highlighting how these innovations are shaping the diagnostic technology landscape. Joe Lennerz will use the example of \u2018AI-powered multiomics platforms\u2019 to illustrate, the complexities of modern diagnostics and how to navigate these challenges using regulatory tools and approaches. Key aspects will include the solutions\u2019 ability to ensure interoperability, conduct safety and effectiveness analyses and enhance diagnostic quality management. Leveraging multiomics holds the promise of driving improvements in patient care and maintaining relevance in the evolving landscape of value-based healthcare.<\/p>\n

\nDetails about the abstracts selected for presentation can be found below:<\/p>\n

\nCapturing Tumor Microenvironment Heterogeneity with an AI-Powered Clinical Multiplex Immunofluorescence Pipeline<\/b><\/p>\n